Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.

The word Cancer hidden in a strand of DNA

Illumina, Inc. announced on 21 September it will buy back cancer screening start-up GRAIL Inc. in a cash and stock deal valued at $8bn, buying out well-known investors such as Amazon’s Jeff Bezos.

Illumina spun out Grail as a separate company four years ago. Grail filed with the

More from In Vitro Diagnostics

More from Diagnostics